876460-94-5

Upstream product

• 876343-11-2 4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1418127-62-4 C₃₁H₃₀F₂N₆O₂ 
• 1418128-20-7 C₂₉H₃₆FN₇O₃ 
• 1418127-77-1 C₃₀H₃₂FN₇O₂ 
• 1418128-35-4 4-[4-(3-amino-5-fluoro-2-methyl-phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid dimethylamide 

Relevant academic research and scientific papers

The condensed heterocyclic compound such as Bruton kinase inhibitors (by machine translation)

The invention relates to a fused heterocycle derivative and an application, which has a structure shown in a formula 1). The compound with the structure shown in the formula 1) has good inhibition effect to Bruton kinases activity, and median inhibitory concentration is lower than 10mol.L generally.

NOVEL PYRROLO PYRIMIDINE DERIVATIVES

The present invention describes new pyrrolo pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel pyrrolo pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.